Chang ML. Metabolic alterations and hepatitis C: From bench to bedside. World J Gastroenterol 2016; 22(4): 1461-1476 [PMID: 26819514 DOI: 10.3748/wjg.v22.i4.1461]
Corresponding Author of This Article
Ming-Ling Chang, MD, PhD, Liver Research Center, Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, No. 5, Fu Hsing Street, Kuei Shan, Taoyuan 33305, Taiwan. mlchang8210@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Topic Highlight
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jan 28, 2016; 22(4): 1461-1476 Published online Jan 28, 2016. doi: 10.3748/wjg.v22.i4.1461
Metabolic alterations and hepatitis C: From bench to bedside
Ming-Ling Chang
Ming-Ling Chang, Liver Research Center, Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Taoyuan 33305, Taiwan
Ming-Ling Chang, Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan 33302, Taiwan
Author contributions: Chang ML analyzed the literatures and wrote the manuscript.
Supported by Grants from the Chang Gung Medical Research Program, No. CMRPG380353, No. CMRPG3B1251, No. CMRPG3B0401, No. CMRPG3B1741, No. CMRPG3B1742 and No. XMRPG3A0521; and the National Science Council, Taiwan, No. 100-2314-B-182-069-, No. 101-2314-B-182-083- and No. 102-2628-B-182-021-MY3.
Conflict-of-interest statement: The author has no conflict of interest to report.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Ming-Ling Chang, MD, PhD, Liver Research Center, Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, No. 5, Fu Hsing Street, Kuei Shan, Taoyuan 33305, Taiwan. mlchang8210@gmail.com
Received: May 29, 2015 Peer-review started: June 4, 2015 First decision: July 14, 2015 Revised: August 14, 2015 Accepted: October 23, 2015 Article in press: October 26, 2015 Published online: January 28, 2016 Processing time: 235 Days and 22.1 Hours
Core Tip
Core tip: Hepatitis C virus (HCV) is thought to cause hypolipidemia, hepatic steatosis, insulin resistance, and diabetes. Its life cycle depends on host cholesterol metabolism. HCV core protein and nonstructural protein 5A perturb crucial metabolic pathways. Many cross-sectional studies have demonstrated increased cardiometabolic risks in HCV patients. Utilizing anti-HCV therapy, most cohort studies have demonstrated the favorable effects of HCV clearance in attenuating cardiometabolic risks. Adipose tissue is an important endocrine organ due to its release of adipocytokines, which strongly regulate metabolism. A comprehensive overview of HCV-associated metabolic and adipocytokine alterations, from bench to bedside, is presented in this topic highlight.
